{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:27:22Z","timestamp":1792466842821,"version":"4.5.0"},"reference-count":55,"publisher":"American Society of Hematology","issue":"18","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,31]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Although tyrosine kinase inhibitor (TKI) therapy has markedly improved the survival of people with chronic-phase chronic myeloid leukemia (CML), 20% to 30% of people still experienced therapy failure. Data from 1955 consecutive patients with chronic-phase CML diagnosed by the European LeukemiaNet recommendations from 1 center receiving initial imatinib or a second-generation (2G) TKI therapy were interrogated to develop a clinical prediction model for TKI-therapy failure. This model was subsequently validated in 3454 patients from 76 other centers. Using the predictive clinical covariates associated with TKI-therapy failure, we developed a model that stratified patients into low-, intermediate- and high-risk subgroups with significantly different cumulative incidences of therapy failure (P\u00a0&amp;lt; .001). There was good discrimination and calibration in the external validation data set, and the performance was consistent with that of the training data set. Our model had the better prediction discrimination than the Sokal and European Treatment and Outcome Study long-term survival scores, with the greater time-dependent area under the receiver-operator characteristic curve values and a better ability to redefine the risk of therapy failure. Our model could help physicians estimate the likelihood of initial imatinib or 2G TKI\u2013therapy failure in people with chronic-phase CML.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024024761","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T17:02:15Z","timestamp":1721840535000},"page":"1951-1961","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy"],"prefix":"10.1182","volume":"144","author":[{"given":"Xiaoshuai","family":"Zhang","sequence":"first","affiliation":[{"name":"1Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingcheng","family":"Liu","sequence":"additional","affiliation":[{"name":"2National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4200-8636","authenticated-orcid":false,"given":"Jian","family":"Huang","sequence":"additional","affiliation":[{"name":"3Department of Hematology, The First Affiliated Hospital of Zhejiang University, College of Medicine, Zhejiang University, Zhejiang, China"},{"name":"4Department of Hematology, The Fourth Affiliated Hospital of Zhejiang University, College of Medicine, Zhejiang University, Zhejiang, China"},{"name":"5Zhejiang Provincial Clinical Research Center for Hematological Disorders, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Zhang","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Xu","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9156-1676","authenticated-orcid":false,"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[{"name":"8Department of Immunology and Inflammation, Centre for Hematology, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Li","sequence":"additional","affiliation":[{"name":"9Department of Hematology, Union hospital, Tongji Medical college, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Liu","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanling","family":"Zhu","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Pan","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2924-7002","authenticated-orcid":false,"given":"Yunfan","family":"Yang","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Lin","sequence":"additional","affiliation":[{"name":"11Department of Hematology, The First Hospital of Jilin University, Jilin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Du","sequence":"additional","affiliation":[{"name":"12Department of Hematology, The Second People\u2019s Hospital of Shenzhen, The First Affiliated Hospital of Shenzhen University, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Liang","sequence":"additional","affiliation":[{"name":"13Department of Hematology, Xijing Hospital, Airforce Military Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Chen","sequence":"additional","affiliation":[{"name":"14Department of Hematology, Qilu Hospital of Shandong University, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Wang","sequence":"additional","affiliation":[{"name":"15Department of Hematology, Sichuan Academy of Medical Sciences Sichuan Provincial People\u2019s Hospital, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohui","family":"Li","sequence":"additional","affiliation":[{"name":"16Department of Hematology, Xi\u2019an international medical center hospital, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuogang","family":"Liu","sequence":"additional","affiliation":[{"name":"17Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0156-699X","authenticated-orcid":false,"given":"Yanqing","family":"Zhang","sequence":"additional","affiliation":[{"name":"18Shenzhen Hospital of Southern Medical University, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenfang","family":"Liu","sequence":"additional","affiliation":[{"name":"19Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianda","family":"Hu","sequence":"additional","affiliation":[{"name":"20Department of Hematology, The Second Affiliated Hospital of Fujian Medical University, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunshui","family":"Liu","sequence":"additional","affiliation":[{"name":"11Department of Hematology, The First Hospital of Jilin University, Jilin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[{"name":"21Center of Hematology, The First Affiliated Hospital of Nanchang University, Nanchang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[{"name":"17Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Meng","sequence":"additional","affiliation":[{"name":"22Department of Hematology, Tongji Hospital of Tongji Medical College, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2658-0803","authenticated-orcid":false,"given":"Yanqiu","family":"Han","sequence":"additional","affiliation":[{"name":"23Department of Hematology, The Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li\u2019e","family":"Lin","sequence":"additional","affiliation":[{"name":"24Department of Hematology, Hainan General Hospital, Hainan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Zhao","sequence":"additional","affiliation":[{"name":"24Department of Hematology, Hainan General Hospital, Hainan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanqing","family":"Tu","sequence":"additional","affiliation":[{"name":"25Department of Hematology, Shenzhen Baoan Hospital, Shenzhen University Second Affiliated Hospital, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caifeng","family":"Zheng","sequence":"additional","affiliation":[{"name":"25Department of Hematology, Shenzhen Baoan Hospital, Shenzhen University Second Affiliated Hospital, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanliang","family":"Bai","sequence":"additional","affiliation":[{"name":"26Department of Hematology, Henan Provincial People\u2019s Hospital, Zhengzhou University People\u2019s Hospital, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeping","family":"Zhou","sequence":"additional","affiliation":[{"name":"27Department of Hematology, The Second Hospital Affiliated to Kunming Medical University, Kunming, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6294-972X","authenticated-orcid":false,"given":"Suning","family":"Chen","sequence":"additional","affiliation":[{"name":"28National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation of Soochow University, Soochow, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"Qiu","sequence":"additional","affiliation":[{"name":"28National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation of Soochow University, Soochow, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijie","family":"Yang","sequence":"additional","affiliation":[{"name":"16Department of Hematology, Xi\u2019an international medical center hospital, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuli","family":"Sun","sequence":"additional","affiliation":[{"name":"29Department of Hematology, The First Affiliated Hospital of Dalian Medical University, Dalian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Sun","sequence":"additional","affiliation":[{"name":"30Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhou","sequence":"additional","affiliation":[{"name":"31Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zelin","family":"Liu","sequence":"additional","affiliation":[{"name":"32Department of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital, Nanshan Hospital, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyu","family":"Wang","sequence":"additional","affiliation":[{"name":"32Department of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital, Nanshan Hospital, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxin","family":"Guo","sequence":"additional","affiliation":[{"name":"33Department of Hematology, The Second Affiliated Hospital of Fujian Medical University, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Pang","sequence":"additional","affiliation":[{"name":"34Department of Hematology, Peking University Shenzhen Hospital, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6887-5255","authenticated-orcid":false,"given":"Qingshu","family":"Zeng","sequence":"additional","affiliation":[{"name":"35Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Suo","sequence":"additional","affiliation":[{"name":"36Department of Hematology, Handan Central Hospital, Handan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Zhang","sequence":"additional","affiliation":[{"name":"37Department of Hematology, First Hospital of Shanxi Medical University, Shanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanjun","family":"Zheng","sequence":"additional","affiliation":[{"name":"37Department of Hematology, First Hospital of Shanxi Medical University, Shanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Huang","sequence":"additional","affiliation":[{"name":"1Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China"},{"name":"38Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China"},{"name":"39State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7131-0522","authenticated-orcid":false,"given":"Qian","family":"Jiang","sequence":"additional","affiliation":[{"name":"1Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China"},{"name":"40Peking University People\u2019s Hospital, Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"11","key":"2024103115204809300_bib1","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/leu.2017.253","article-title":"Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants","volume":"31","author":"Hehlmann","year":"2017","journal-title":"Leukemia"},{"issue":"10","key":"2024103115204809300_bib2","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2024103115204809300_bib3","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"2024103115204809300_bib4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/leu.2015.261","article-title":"Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia","volume":"30","author":"Pfirrmann","year":"2016","journal-title":"Leukemia"},{"issue":"suppl 2","key":"2024103115204809300_bib5","doi-asserted-by":"crossref","first-page":"S209","DOI":"10.1007\/s00277-015-2316-0","article-title":"Prognostic scores for patients with chronic myeloid leukemia under particular consideration of competing causes of death","volume":"94","author":"Pfirrmann","year":"2015","journal-title":"Ann Hematol"},{"issue":"2","key":"2024103115204809300_bib6","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41375-021-01387-y","article-title":"Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?","volume":"36","author":"Zhang","year":"2022","journal-title":"Leukemia"},{"issue":"6","key":"2024103115204809300_bib7","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.3109\/10428194.2014.974047","article-title":"Molecular responses at 3 and 6 months after switching to a second-generation tyrosine kinase inhibitor are complementary and predictive of long-term outcomes in patients with chronic myeloid leukemia who fail imatinib","volume":"56","author":"Boquimpani","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2024103115204809300_bib8","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1007\/s00277-021-04544-6","article-title":"Adolescents experienced more treatment failure than children with chronic myeloid leukemia receiving imatinib as frontline therapy: a retrospective multicenter study","volume":"100","author":"Dou","year":"2021","journal-title":"Ann Hematol"},{"issue":"10","key":"2024103115204809300_bib9","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/ajh.25907","article-title":"The clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia","volume":"95","author":"Ohanian","year":"2020","journal-title":"Am J Hematol"},{"issue":"2","key":"2024103115204809300_bib10","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00432-021-03624-4","article-title":"Impact of socio-demographic co-variates on prognosis, tyrosine kinase-inhibitor use and outcomes in persons with newly-diagnosed chronic myeloid leukaemia","volume":"148","author":"Yu","year":"2022","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"5","key":"2024103115204809300_bib11","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/s41375-023-01875-3","article-title":"Validation of the imatinib-therapy failure model","volume":"37","author":"Zhang","year":"2023","journal-title":"Leukemia"},{"issue":"6","key":"2024103115204809300_bib12","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/j.clml.2024.02.008","article-title":"Comparison of the efficacy among nilotinib, dasatinib, flumatinib and imatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients: a real-world multi-center retrospective study","volume":"24","author":"Zhang","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"2024103115204809300_bib13","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41375-022-01527-y","article-title":"A\u00a0predictive scoring system for therapy-failure in persons with chronic myeloid leukemia receiving initial imatinib therapy","volume":"36","author":"Zhang","year":"2022","journal-title":"Leukemia"},{"issue":"9","key":"2024103115204809300_bib14","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"issue":"19","key":"2024103115204809300_bib15","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2024103115204809300_bib16","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic\u00a0myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2024103115204809300_bib17","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","article-title":"European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor","volume":"112","author":"Marin","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2024103115204809300_bib18","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3324\/haematol.2009.012781","article-title":"Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia","volume":"95","author":"Milojkovic","year":"2010","journal-title":"Haematologica"},{"issue":"6","key":"2024103115204809300_bib19","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1046\/j.1365-2141.2003.04200.x","article-title":"The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia","volume":"120","author":"Wang","year":"2003","journal-title":"Br J Haematol"},{"issue":"35","key":"2024103115204809300_bib20","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2024103115204809300_bib21","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2024103115204809300_bib22","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"issue":"4","key":"2024103115204809300_bib23","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"7","key":"2024103115204809300_bib24","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"2024103115204809300_bib25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.6004\/jnccn.2024.0007","article-title":"Chronic myeloid leukemia, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Shah","year":"2024","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"14","key":"2024103115204809300_bib26","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1080\/10428194.2023.2255804","article-title":"Validation of imatinib therapy failure score (IMTF) in chronic phase chronic myeloid leukemia in real life practice","volume":"64","author":"Ielo","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2024103115204809300_bib27","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \"good-risk\" chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"issue":"22","key":"2024103115204809300_bib28","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood-2016-01-690230","article-title":"Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"issue":"9","key":"2024103115204809300_bib29","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.leukres.2013.06.003","article-title":"Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level?","volume":"37","author":"Qin","year":"2013","journal-title":"Leuk Res"},{"issue":"25","key":"2024103115204809300_bib30","doi-asserted-by":"crossref","first-page":"5963","DOI":"10.1182\/blood-2011-10-383711","article-title":"Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet","volume":"119","author":"Guilhot","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2024103115204809300_bib31","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1055\/s-0038-1634008","article-title":"Building multivariable regression models with continuous covariates in clinical epidemiology--with an emphasis on fractional polynomials","volume":"44","author":"Royston","year":"2005","journal-title":"Methods Inf Med"},{"issue":"12","key":"2024103115204809300_bib32","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.1016\/j.csda.2005.07.015","article-title":"Multivariable regression model building by using fractional polynomials: description of SAS, STATA and R programs","volume":"50","author":"Sauerbrei","year":"2006","journal-title":"Comput Stat Data Anal"},{"issue":"18","key":"2024103115204809300_bib33","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1002\/sim.5762","article-title":"Model selection in competing risks regression","volume":"32","author":"Kuk","year":"2013","journal-title":"Stat Med"},{"issue":"2","key":"2024103115204809300_bib34","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1037\/a0027127","article-title":"Model selection and psychological theory: a discussion of the differences between the Akaike information criterion (AIC) and the Bayesian information criterion (BIC)","volume":"17","author":"Vrieze","year":"2012","journal-title":"Psychol Methods"},{"issue":"2","key":"2024103115204809300_bib35","first-page":"194","article-title":"On the problem of using 'optimal' cutpoints in the assessment of quantitative prognostic factors","volume":"24","author":"Holl?Nder","year":"2001","journal-title":"Onkologie"},{"issue":"6","key":"2024103115204809300_bib36","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nmeth.3414","article-title":"Sampling distributions and the bootstrap","volume":"12","author":"Kulesa","year":"2015","journal-title":"Nat Methods"},{"issue":"8","key":"2024103115204809300_bib37","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0006-3223(98)00043-2","article-title":"Multiple correlations and Bonferroni's correction","volume":"44","author":"Curtin","year":"1998","journal-title":"Biol Psychiatry"},{"issue":"5","key":"2024103115204809300_bib38","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2967\/jnumed.120.251520","article-title":"Statistical considerations in the evaluation of continuous biomarkers","volume":"62","author":"Polley","year":"2021","journal-title":"J\u00a0Nucl Med"},{"issue":"1, 20","key":"2024103115204809300_bib39","article-title":"Kernel density estimation, kernel methods, and fast learning in large data sets","volume":"44","author":"Wang","year":"2014","journal-title":"IEEE Trans Cybern"},{"key":"2024103115204809300_bib40","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jclinepi.2015.12.005","article-title":"A\u00a0calibration hierarchy for risk models was defined: from utopia to empirical data","volume":"74","author":"Van Calster","year":"2016","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"1","key":"2024103115204809300_bib41","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12874-017-0332-6","article-title":"Time-dependent ROC curve analysis in medical research: current methods and applications","volume":"17","author":"Kamarudin","year":"2017","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"2024103115204809300_bib42","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.eururo.2018.08.038","article-title":"Reporting and interpreting decision curve analysis: a guide for investigators","volume":"74","author":"Van Calster","year":"2018","journal-title":"Eur Urol"},{"issue":"1","key":"2024103115204809300_bib43","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/BSD.0000000000001055","article-title":"Propensity score matching: a powerful tool for analyzing observational nonrandomized data","volume":"34","author":"Badhiwala","year":"2021","journal-title":"Clin Spine Surg"},{"issue":"3","key":"2024103115204809300_bib44","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/BSD.0000000000000932","article-title":"Propensity score matching: a statistical method","volume":"33","author":"Kane","year":"2020","journal-title":"Clin Spine Surg"},{"issue":"27","key":"2024103115204809300_bib45","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/sim.7501","article-title":"Practical recommendations for reporting Fine-Gray model analyses for competing risk data","volume":"36","author":"Austin","year":"2017","journal-title":"Stat Med"},{"issue":"1","key":"2024103115204809300_bib46","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11657-020-00748-x","article-title":"A\u00a0comparison of the Cox model to the Fine-Gray model for survival analyses of re-fracture rates","volume":"15","author":"Nolan","year":"2020","journal-title":"Arch Osteoporos"},{"issue":"9","key":"2024103115204809300_bib47","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/bmt.2009.359","article-title":"Regression modeling of competing risk using R: an in depth guide for clinicians","volume":"45","author":"Scrucca","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"23","key":"2024103115204809300_bib48","doi-asserted-by":"crossref","first-page":"8931","DOI":"10.1002\/cam4.3516","article-title":"The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort","volume":"9","author":"Sato","year":"2020","journal-title":"Cancer Med"},{"key":"2024103115204809300_bib49","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.2147\/CMAR.S237467","article-title":"Validation of the EUTOS long-term survival score in chinese chronic myeloid leukemia patients treated with imatinib: a multicenter real-world study","volume":"12","author":"Yang","year":"2020","journal-title":"Cancer Manag Res"},{"issue":"4","key":"2024103115204809300_bib50","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1182\/bloodadvances.2020003570","article-title":"Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression","volume":"5","author":"Clark","year":"2021","journal-title":"Blood Adv"},{"issue":"26","key":"2024103115204809300_bib51","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1182\/bloodadvances.2017011858","article-title":"Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy","volume":"1","author":"Gong","year":"2017","journal-title":"Blood Adv"},{"issue":"8","key":"2024103115204809300_bib52","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1038\/s41375-020-0826-9","article-title":"High-risk additional chromosomal abnormalities at low blast counts herald death by CML","volume":"34","author":"Hehlmann","year":"2020","journal-title":"Leukemia"},{"issue":"20","key":"2024103115204809300_bib53","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Na\u00efve Chronic Myeloid Leukemia Patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024103115204809300_bib54","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1158\/1078-0432.CCR-20-1600","article-title":"Flumatinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: a phase iii, randomized, open-label, multi-center FESTnd Study","volume":"27","author":"Zhang","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2024103115204809300_bib55","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1038\/leu.2013.171","article-title":"The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib","volume":"27","author":"Hoffmann","year":"2013","journal-title":"Leukemia"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/18\/1951\/2311646\/blood_bld-2024-024761-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/18\/1951\/2311646\/blood_bld-2024-024761-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T15:21:01Z","timestamp":1730388061000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/144\/18\/1951\/517139\/A-predictive-model-for-therapy-failure-in-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,31]]},"references-count":55,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2024,10,31]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024024761","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,31]]}}}